Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711274 | 0.88 | MCL1 (0.55) | ALDH1A1HPGDFAAHGAASMN1; SMN2 | |
| SCHEMBL23037197 | 0.87 | MAPT (0.54) | ALDH1A1FAAHCES1GAARAB9A | |
| SCHEMBL29595815 | 0.87 | MAPT (0.54) | ALDH1A1FAAHCES1GAARAB9A | |
| SCHEMBL483444 | 0.87 | MAPT (0.56) | ALDH1A1HPGDHSD17B10FAAHKAT6A | |
| SCHEMBL28213723 | 0.87 | IRAK4 (0.48) | ALDH1A1FAAHCES1GAARAB9A | |
| SCHEMBL11297183 | 0.85 | MAPT (0.61) | RAB9ASMN1; SMN2 | |
| SCHEMBL25002897 | 0.85 | MAPT (0.58) | ALDH1A1KDM4ECNR2CNR1RAB9A | |
| SCHEMBL25002929 | 0.85 | ADORA3 (0.52) | ALDH1A1KDM4EHPGDHSD17B10FAAH | |
| SCHEMBL11158237 | 0.85 | SCN10A (0.45) | FAAHCES1GAARAB9ASMN1; SMN2 | |
| SCHEMBL14008675 | 0.85 | FAAH (0.52) | ALDH1A1KDM4EHPGDHSD17B10FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354897-B | Substituted 1,2, 4-triazole, pyridine and pyrimidine derivatives and application thereof in medicines | 华东师范大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-116354897-A | Substituted 1,2, 4-triazole, pyridine and pyrimidine derivatives and application thereof in medicines | 华东师范大学 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1663975-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060100427-A1 | Novel Gamma Secretase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1472223-A1 | GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040048848-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2003066592-A1 | GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | ALDH1A1 4012/4885KDM4E 2433/4885HPGD 3814/4885 |
| US-20040048848-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, PSEN1 | ALDH1A1 1953/4885KDM4E 1995/4885HPGD 3246/4885 |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | ALDH1A1 2255/4885KDM4E 947/4885HPGD 2136/4885 |
| US-20060100427-A1 | Novel Gamma Secretase inhibitors | BACE1, BACE2, PSEN1 | ALDH1A1 1610/4885KDM4E 1998/4885HPGD 2996/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | ALDH1A1 2742/4885KDM4E 2865/4885HPGD 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.